ClinicalTrials.gg
RecruitingNCT06106945Updated Oct 30, 2026

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

A Phase 1/2 interventional study of AZD0305 and Elranatamab in Multiple Myeloma, sponsored by AstraZeneca. Recruiting at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 30, 2026First site in United KingdomSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
226
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Multiple Myeloma by AstraZeneca — 8 open to participants now, 8 under way, 3 of them phase 3. Multiple Myeloma · AstraZeneca.

Planned enrollment
5th of 16
226 · median 104
Started
2023
with 2 others
Phase 1/2
7 of 16
4 open now
Registered
10th of 16
by date

Among the 16 studies in Multiple Myeloma by AstraZeneca, this one is the 5th largest by planned enrollment, is one of 3 that started in 2023, is one of 7 in phase 1/2, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

8 of the 16 studies in Multiple Myeloma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Multiple Myeloma by AstraZeneca, or all of them as a file.
02

Study summary

This is a Phase I/II, modular, open-label, multicenter, dose escalation, and dose expansion/optimization study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics and efficacy of AZD0305 as monotherapy and in combination with other anticancer agents in participants with MM.

Read the detailed description

This study will follow a modular protocol design evaluating AZD0305 as monotherapy and in combination with other anticancer agents. The protocol may be amended in the future to incorporate further monotherapy expansion at the recommended Phase 2 dose (RP2D) in Phase II, and/or additional modules investigating AZD0305 in combination with other anticancer agents.

The study consists of 3 modules:

  • Module 1 (AZD0305 monotherapy),
  • Module 2 (AZD0305 in combination with elranatamab)
  • Module 3 (AZD0305 in combination with pomalidomide and dexamethasone [Pd])
03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • GPRC5D
  • ADC
  • AZD0305
  • Multiple Myeloma
  • MM
  • MMAE
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
  • performance status of ≤ 2 in module 1, or 0 or 1 in modules 2 and 3
  • Documentation of Multiple Myeloma (MM) as defined by International Myeloma Working Group (IMWG) Diagnostic Criteria for Multiple Myeloma. Site should ensure that Multiple Myeloma diagnosis is confirmed in accordance with the IMWG Diagnostic Criteria
  • Participants must have one or more criteria for Serum M-Protein, Urine M-protein, and Serum immunoglobulin free light chains as specified in the relevant module of the CSP;
  • Adequate organ and bone marrow function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP as relevant to each module.
  • Participants must have received at least 3 in module 1. In modules 2 and 3, participants must meet the phase-specific requirements for the number of prior lines of therapy.
  • The above is a summary of key criteria, other module specific inclusion criteria details may apply

Key Exclusion Criteria:

  • Amyloidosis, plasma cell leukemia, Waldenstrom Macroglobulinemia, Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin Syndrome, or Smoldering Multiple Myeloma(compliant with WHO criteria);
  • Participants who have previously received anti-GPRC5D or MMAE-containing treatment
  • Participants with a history of prior other than MM within 3 years prior to first dose of study intervention. some exceptions apply Participants with previous history of active John Cunningham virus infection resulting in PML
  • Participants with a known toAZD0305 or any of the of the productor to any of the drugs included in the respective modules or who experienced Grade 3 or higher hypersensitivity to prior mono clonal antibody therapy
  • Participants who have uncontrolled severe illness including but not limited to ongoing active infection requiring therapeutic antibiotics and/or other administration
  • Participants who have previously received allogenic stem cell transplant, or participant has received stem cell transplant within 3months before the first dose of study intervention
  • Participants exhibiting clinical signs of central nervous system involvement of MM;
  • Participants with known history of severe or very severe , or previous history of non-infectious ILD/pneumonitis that has required oral or IV of supplemental oxygen, or where suspected suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Participants with known severe persistent asthma within the past 5 years, or uncontrolled asthma of any classification;
  • Participants who have severe cardio vascular disease which is not adequately controlled.
  • Participants who have a history of immunodeficiency disease.
  • Participants with peripheral neuropathy ≥ Grade2.
  • Primary MM.
  • The above is a summary of key criteria, other exclusion criteria details may apply
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    AZD0305 monotherapy

    Module 1: Phase Ia: Dose Escalation Phase Ib: Dose Expansion/Optimization AZD0305 will be administered at specified dose levels.

    Drug: AZD0305

  • Experimental
    AZD0305 + Elranatamab

    Module2: Phase 1a: Dose escalation and Phase 1b: Backfills, AZD0305 will be administered in combination with elranatamab, following the module-specific dosing.

    Drug: AZD0305 · Drug: Elranatamab

  • Experimental
    AZD0305 + Pomalidomide and Dexamethasone

    Module3: Phase 1a: Dose escalation and Phase 1b: Backfills, AZD0305 will be administered in combination with pomalidomide and dexamethasone, following the module-specific dosing.

    Drug: AZD0305 · Drug: Pomalidomide · Drug: Dexamethasone

Interventions

  • DrugAZD0305

    AZD0305 Investigational product

  • Module 2 Investigational product

  • Module 3 Standard of Care (background treatment)

  • Module 3 Standard of Care (background treatment)

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only)

    A DLT is any toxicity occuring from the first dose of AZD0305 up to and including the planned end of Cycle 1 (the DLT assessment period) that is assessed as unrelated to the disease or disease-related processes under investigation and which includes, any death not clearly due to the underlying disease or extraneous causes, pre-defined haematological and non-haematological toxicities

    Time frame: From first dose of AZD0305 until the end of Cycle 1. Cycle 1 (the DLT assessment period is 21 days for Module 1 Group A and 28 days for Module 1 Group B, Module 2, and Module 3)

  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Number of patients with adverse events and serious adverse events by system organ class and preferred term

    Time frame: From time of Informed consent to 30 days post end of treatment

  3. Frequency of dose modifications, dose delays, and treatment discontinuations due to AEs (Module 2 and Module 3)

    Number and percentage of participants with dose modifications, dose delays, and permanent discontinuations due to adverse events (for AZD0305 and combination agent\[s\], as applicable), per protocol-defined dose modification rules.

    Time frame: From first dose of study treatment until End of treatment (EOT), assessed up to approximately 2 years (each cycle is 28 days)

Secondary outcomes

  1. Phase Ia: Objective Response Rate (ORR)

    The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria

    Time frame: From first dose of AZD0305 to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)

  2. Phase Ia: Duration of response (DoR)

    The time from the date of first response until date of disease progression or death in the absence of disease progression

    Time frame: From the first documented response to confirmed progressive disease or death (approximately 2 years)

  3. Phase Ia: Progression free Survival (PFS)

    The time from first dose until IMWG defined disease progression or death

    Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)

  4. Phase Ia: Overall Survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause

    Time frame: From first dose of AZD0305 to death (approximately 2 years)

  5. Phase Ia: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  6. Phase Ia: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  7. Phase Ia: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)

    Time to maximum observed plasma concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  8. Phase Ia: Pharmacokinetics of AZD0305: Clearance

    A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  9. Phase Ia: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)

    Terminal elimination half-life

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  10. Phase Ia: Immunogenicity of AZD0305

    The number and percentage of participants who develop ADAs

    Time frame: From the first dose of study intervention, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  11. Phase Ia: Immunogenicity of elranatamab

    The number and percentage of participants who develop ADAs

    Time frame: From the first dose, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years)

  12. Phase Ia: MRD negative CR rate

    The percentage of patients who achieve a complete response (CR) and have minimal residual disease (MRD) negativity in bone marrow.

    Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)

  13. Phase Ib: Objective Response Rate (ORR)

    The percentage of patients with a confirmed investigator assessed sCR, CR, VGPR or PR according to IMWG criteria

    Time frame: From randomization/cohort assignment to progressive disease or Initiation of subsequent MM therapy (approximately 2 years)

  14. Phase Ib: Duration of response (DoR)

    The time from date of first response until date of disease progression or death in the absence of disease progression

    Time frame: From randomization/cohort assignment to confirmed progressive disease or death (approximately 2 years)

  15. Phase Ib: Progression free Survival (PFS)

    The time from randomization until IMWG defined disease progression or death

    Time frame: From randomization/cohort assignment to progressive disease or death in the absence of disease progression (approximately 2 years)

  16. Phase Ib: Overall Survival (OS)

    The time from randomization until death due to any cause

    Time frame: From randomization/cohort assignment to death (approximately 2 years)

  17. Phase Ib: Pharmacokinetics of AZD0305: Area Under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve

    Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  18. Phase Ib: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax)

    Maximum observed plasma concentration of the study drug

    Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  19. Phase Ib: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax)

    Time to maximum observed plasma concentration of the study drug

    Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  20. Phase Ib: Pharmacokinetics of AZD0305: Clearance

    A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time

    Time frame: From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years

  21. Phase Ib: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2)

    Terminal elimination half-life

    Time frame: From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  22. Phase Ib: Immunogenicity of AZD0305

    The number and percentage of participants who develop ADAs

    Time frame: From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years)

  23. Phase Ib: Immunogenicity of elranatamab

    The number and percentage of participants who develop ADAs

    Time frame: From the first dose, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years)

  24. Phase 1b: MRD negative CR rate (Module 2 and Module 3)

    The percentage of patients who achieve a complete response (CR) and have minimal residual disease (MRD) negativity in bone marrow.

    Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)

  25. Complete Response Rate (CRR) - Mod2&3 only

    Percentage of participants achieving a confirmed CR or sCR per IMWG criteria.

    Time frame: From first dose of combination treatment to progressive disease or initiation of subsequent multiple myeloma therapy (approximately 2 years)

  26. Pre-Dose Plasma Concentration of Elranatamab (pharmacokinetics - Module 2 only)

    Pre-dose Plasma concentrations for elranatamab.

    Time frame: From the first dose of study intervention, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years; 1 cycle = 28 days)

07

Study locations

35 of 46 sites recruiting
  • Research Site
    Duarte, California 91010, United States
    Recruiting
  • Research Site
    Irvine, California 92618, United States
    Recruiting
  • Research Site
    Atlanta, Georgia 30322, United States
    Recruiting
  • Research Site
    Boston, Massachusetts 02215, United States
    Recruiting
  • Research Site
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Research Site
    St Louis, Missouri 63110, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    New York, New York 10065, United States
    Recruiting
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Research Site
    Fairfax, Virginia 22031, United States
    Recruiting
  • Research Site
    Fitzroy, VIC3065, Australia
    Recruiting
  • Research Site
    Melbourne, 3000, Australia
    Recruiting
  • Research Site
    Nedlands, 6009, Australia
    Recruiting
  • Research Site
    Wollongong, 2500, Australia
    Not yet recruiting
  • Research Site
    Salvador, 41253-190, Brazil
    Not yet recruiting
  • Research Site
    São Paulo, 04537-080, Brazil
    Recruiting
  • Research Site
    São Paulo, 05652000, Brazil
    Recruiting
  • Research Site
    Hamilton, Ontario L8V 5C2, Canada
    Recruiting
  • Research Site
    Ottawa, Ontario K1H 8L6, Canada
    Recruiting
  • Research Site
    Toronto, Ontario M5G 2M9, Canada
    Not yet recruiting
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
    Recruiting
  • Research Site
    Nova Scotia, B3H 1V7, Canada
    Not yet recruiting
  • Research Site
    Beijing, 100044, China
    Recruiting
  • Research Site
    Changsha, 410013, China
    Recruiting
  • Research Site
    Guangzhou, 510060, China
    Recruiting
  • Research Site
    Shenyang, 110134, China
    Recruiting
  • Research Site
    Lille, 59037, France
    Recruiting
  • Research Site
    Nantes, 44000, France
    Recruiting
  • Research Site
    Essen, 45147, Germany
    Recruiting
  • Research Site
    Freiburg im Breisgau, 79106, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Hamburg, 20246, Germany
    Recruiting
  • Research Site
    Heidelberg, 69120, Germany
    Not yet recruiting
  • Research Site
    Lübeck, 23538, Germany
    Recruiting
  • Research Site
    Nuremberg, 90419, Germany
    Recruiting
  • Research Site
    Tübingen, 72076, Germany
    Not yet recruiting
  • Research Site
    Würzburg, 97080, Germany
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Recruiting
  • Research Site
    Nagoya, 467-8602, Japan
    Recruiting
  • Research Site
    Yamagata, 990-9585, Japan
    Recruiting
  • Research Site
    Badalona, 8916, Spain
    Recruiting
  • Research Site
    Madrid, 28027, Spain
    Recruiting
  • Research Site
    Madrid, 28041, Spain
    Recruiting
  • Research Site
    Pamplona, 31005, Spain
    Recruiting
  • Research Site
    Salamanca, 37007, Spain
    Recruiting
  • Research Site
    Leeds, LS9 7TF, United Kingdom
    Not yet recruiting
  • Research Site
    Manchester, M20 4BX, United Kingdom
    Not yet recruiting
  • Research Site
    Plymouth, PL6 8DH, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jan 2028, 49 months after the start.

Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 49 months is below that.

Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Aug 2027 → Jan 2028 and completion Aug 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2023
First posted
Oct 30, 2023
StartActual
Dec 5, 2023
Primary completionEst.
Jan 24, 2028was Aug 2027
CompletionEst.
Jan 24, 2028was Aug 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in United Kingdom. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Research Site · São Paulo, BrazilNot yet recruiting→Recruiting
  • Research Site · Badalona, SpainNot yet recruiting→Recruiting
Show 3 added (3 United Kingdom)
  • Research Site · Leeds, United Kingdom
  • Research Site · Manchester, United Kingdom
  • Research Site · Plymouth, United Kingdom
Oct 30, 2026
Primary completion
Aug 16, 2027→Jan 24, 2028
Oct 30, 2026
Study completion
Aug 16, 2027→Jan 24, 2028
Oct 30, 2026
Eligibility
10 criteria edited, 2 removed
What changed in the criteria
  • EditedParticipants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
  • Removedin which the study is taking place;
  • EditedParticipants must have received at least 3 prior lines of treatment in module 1, or 1-3 prior lines in. In modules 2 and 3, with additional moduleparticipants must meet the phase-specific requirements related tofor the number of prior lines of therapy.
  • EditedThe above is a summary of key criteria, other module specific inclusion criteria details may apply
  • EditedParticipants with a history of prior malignancy other than MM within 3 years prior to first dose of study intervention. some exceptions apply; Participants with previous history of active John Cunningham virus infection resulting in PML
  • RemovedParticipants with previous history of active JC virus infection resulting in PML;
  • EditedParticipants with a known hypersensitivity to AZD0305toAZD0305 or any of the excipients of the product orproductor to any of the drugs included in the respective modules or who experienced Grade 3 or higher hypersensitivity to prior monoclonalmono clonal antibody therapy;
  • EditedParticipants who have previously received allogenic stem cell transplant, or participant has received autologous stem cell transplant within 3 months3months before the first dose of study intervention;
  • ChangedBefore Participants with known COPD, or previous history of ILD/pneumonitis;Now Participants with known history of severe or very severe COPD, or previous history of non-infectious ILD/pneumonitis that has required oral or IV steroids of supplemental oxygen, or where suspected suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • EditedParticipants with known moderate or severe persistent asthma within the past 5 years, or uncontrolled asthma of any classification;
  • EditedParticipants who have severe cardiovascularcardio vascular disease which is not adequately controlled;.
  • EditedParticipants with peripheral neuropathy ≥ Grade 2;Grade2.
Oct 30, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPhase 1b: MRD negative CR rate (Module 2 and Module 3)Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    3 sites added — first site in United Kingdom. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Research Site · São Paulo, BrazilNot yet recruiting→Recruiting
    • Research Site · São Paulo, BrazilNot yet recruiting→Recruiting
    • Research Site · Badalona, SpainNot yet recruiting→Recruiting
    Show 3 added (3 United Kingdom)
    • Research Site · Leeds, United Kingdom
    • Research Site · Manchester, United Kingdom
    • Research Site · Plymouth, United Kingdom
    Primary completion Aug 16, 2027→Jan 24, 2028
    Study completion Aug 16, 2027→Jan 24, 2028
    Eligibility 10 criteria edited, 2 removed
    What changed in the criteria
    • EditedParticipants must be at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place.
    • Removedin which the study is taking place;
    • EditedParticipants must have received at least 3 prior lines of treatment in module 1, or 1-3 prior lines in. In modules 2 and 3, with additional moduleparticipants must meet the phase-specific requirements related tofor the number of prior lines of therapy.
    • EditedThe above is a summary of key criteria, other module specific inclusion criteria details may apply
    • EditedParticipants with a history of prior malignancy other than MM within 3 years prior to first dose of study intervention. some exceptions apply; Participants with previous history of active John Cunningham virus infection resulting in PML
    • RemovedParticipants with previous history of active JC virus infection resulting in PML;
    • EditedParticipants with a known hypersensitivity to AZD0305toAZD0305 or any of the excipients of the product orproductor to any of the drugs included in the respective modules or who experienced Grade 3 or higher hypersensitivity to prior monoclonalmono clonal antibody therapy;
    • EditedParticipants who have previously received allogenic stem cell transplant, or participant has received autologous stem cell transplant within 3 months3months before the first dose of study intervention;
    • ChangedBefore Participants with known COPD, or previous history of ILD/pneumonitis;Now Participants with known history of severe or very severe COPD, or previous history of non-infectious ILD/pneumonitis that has required oral or IV steroids of supplemental oxygen, or where suspected suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
    • EditedParticipants with known moderate or severe persistent asthma within the past 5 years, or uncontrolled asthma of any classification;
    • EditedParticipants who have severe cardiovascularcardio vascular disease which is not adequately controlled;.
    • EditedParticipants with peripheral neuropathy ≥ Grade 2;Grade2.
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPhase 1b: MRD negative CR rate (Module 2 and Module 3)Time frame: From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06106945
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Dec 5, 2023
Primary completion
Jan 24, 2028 (estimated)
Completion
Jan 24, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion